SavedAdd your journal

Journals / Turkish Journal of Biology / 2021 / Cilt: 45 - Sayı: 1

Effects of bradykinin on proliferation, apoptosis, and cycle of glomerular mesangial cells via the TGF-beta 1/Smad signaling pathway

Ji DONG
Li DİNG
Liuwei WANG
Zijun YANG
Yulin WANG
Ying ZANG
Xuexia CAO
Lin TANG
Pages
17–25
Publication Date
2021-02-09
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

BK regulates the proliferation, apoptosis, and the cycle of glomerular mesangial cells by inhibiting the TGF-beta 1/Smad signaling pathway.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We aimed to assess the effects of bradykinin (BK) on the proliferation, apoptosis, and cycle of glomerular mesangial cells via the transforming growth factor-beta 1 (TGF-beta 1)/Smad signaling pathway.
📊
Key Findings & Data:Rat glomerular mesangial cells, HBZY-1, were divided into normal group (untreated), model group (5 ng/L TGF-beta 1), BK group (5 ng/L TGF-beta 1 + 1 ng/L BK), and inhibitor group [5 ng/L TGF-beta 1 + 1 ng/L LY2109761 (TGF-beta 1-specific inhibitor)].
💡
Conclusion & Impact:BK regulates the proliferation, apoptosis, and the cycle of glomerular mesangial cells by inhibiting the TGF-beta 1/Smad signaling pathway.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Glomerular mesangial cell · bradykinin · TGF-β1

Abstract

We aimed to assess the effects of bradykinin (BK) on the proliferation, apoptosis, and cycle of glomerular mesangial cells via the transforming growth factor-beta 1 (TGF-beta 1)/Smad signaling pathway. Rat glomerular mesangial cells, HBZY-1, were divided into normal group (untreated), model group (5 ng/L TGF-beta 1), BK group (5 ng/L TGF-beta 1 + 1 ng/L BK), and inhibitor group [5 ng/L TGF-beta 1 + 1 ng/L LY2109761 (TGF-beta 1-specific inhibitor)]. The cell proliferation, cycle, apoptosis, expression of type I collagen (Col-1), and protein expressions of Col-1, TGF-beta 1, and phosphorylated Smad2 (p-Smad2) were detected by EdU labeling, flow cytometry, acridine orange/ethidium bromide (AO/EB) dual staining, immunofluorescence assay, and Western blotting, respectively. Compared with the normal group, the cell proliferation rate (P = 0.02) and protein expression levels of Col-1 (P = 0.02), TGF-beta 1 (P = 0.01), p-Smad2 (P = 0.02), and p-Smad7 (P = 0.00) in the model group significantly increased, and apoptosis rate (P = 0.01) significantly decreased. Compared with the model group, the BK and inhibitor groups significantly decreased in proliferation rate (P = 0.01) and protein expression levels of Col-1 (P = 0.01), TGF-beta 1 (P = 0.01), and p-Smad2 (P = 0.00). Also, they were significantly elevated in apoptosis rate (P = 0.02) and p-Smad7 protein expression (P = 0.02). BK regulates the proliferation, apoptosis, and the cycle of glomerular mesangial cells by inhibiting the TGF-beta 1/Smad signaling pathway.

🔖

Cite This Article

DONG, J., DİNG, L., WANG, L., YANG, Z., WANG, Y., ZANG, Y., CAO, X., TANG, L. (2021). Effects of bradykinin on proliferation, apoptosis, and cycle of glomerular mesangial cells via the TGF-beta 1/Smad signaling pathway. Turkish Journal of Biology, Cilt: 45 - Sayı: 1, 17–25. https://ajindex.com/articles/192661

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Catalan M, 2019, MOL BIOL REP, V46, P5197, DOI 10.1007/s11033-019-04977-3 Cheng X, 2019, NEPHROL DIAL TRANSPL, V34, P242, DOI 10.1093/ndt/gfy107 Cui K, 2017, ASIAN J ANDROL, V19, P67, DOI 10.4103/1008-682X.189209 Deres L, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00624 Fahmy SR, 2019, TOXICOL LETT, V301, P73, DOI 10.1016/j.toxlet.2018.11.006 Hsieh CC, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0915-0 Acuna MJ, 2018, J CELL COMMUN SIGNAL, V12, P589, DOI 10.1007/s12079-017-0439-x Kim YM, 2008, CELL SIGNAL, V20, P1882, DOI 10.1016/j.cellsig.2008.06.021 Kocer G, 2018,
  2. NEPHRON, V139, P299, DOI 10.1159/000489506 Lee EJ, 2018,
  3. NUTRIENTS, V10, DOI 10.3390/nu10070882 Liu HF, 2018, ACTA PHARMACOL SIN, V39, P222, DOI 10.1038/aps.2017.87 Ma LB, 2018, INT UROL NEPHROL, V50, P373, DOI 10.1007/s11255-017-1757-x Metz GE, 2019, BIOTECH HISTOCHEM, V94, P115, DOI 10.1080/10520295.2018.1521989 Nguyen C, 2019, CLIN KIDNEY J, V12, P232, DOI 10.1093/ckj/sfy068 Nokkari A, 2018, PROG NEUROBIOL, V165, P26, DOI 10.1016/j.pneurobio.2018.01.003 Pereira AV, 2010, ARCH IMMUNOLOGIAE TH, V68, P3 Qin L, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-018-1774-x Shi JX, 2018, CHINESE J CLIN PHARM, V264, P42 Song Y, 2017, INT IMMUNOPHARMACOL, V44, P115, DOI 10.1016/j.intimp.2017.01.008 Wang Y, 2014, MOL CELL ENDOCRINOL, V382, P979, DOI 10.1016/j.mce.2013.11.018 Wei QQ, 2018, MOL MED REP, V17, P5878, DOI 10.3892/mmr.2018.8556 Weng YZ, 2019, INT J MOL MED, V44, P927, DOI 10.3892/ijmm.2019.4260 Wu R, 2018,
  4. METABOLISM, V83, P18, DOI 10.1016/j.metabol.2018.01.002 Zhang HL, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108705 Zhang S, 2019, EUR J PHARMACOL, V845, P74, DOI 10.1016/j.ejphar.2018.12.033 Zhu LP, 2018, BIOL RES, V51, DOI 10.1186/s40659-018-0157-8 Zhu Y, 2019, EUR REV MED PHARMACO, V23, P5535, DOI 10.26355/eurrev_201907_18286